Reduced latent inhibition in people with schizophrenia: An effect of psychosis or of its treatment

British Journal of Psychiatry

Volumn 172, Issue MAR., 1998, Pages 243-249

  Williams, J H ^a   Wellman, N A ^a   Geaney, D P ^b   Cowen, P J ^b   Feldon, J ^c   Rawlins, J N P ^b,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Department of Psychiatry ^*  (United Kingdom)

^c Institute of Pharmacology and Toxicology   (Switzerland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTENTION; AUDITORY STIMULATION; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LATENT INHIBITION; LEARNING; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PSYCHOSIS; SCHIZOPHRENIA; STIMULUS RESPONSE; TASK PERFORMANCE; TREATMENT OUTCOME;

EID: 0031937968     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.172.3.243     Document Type: Article

References (32)

1. Allan, L. M., Williams, J. H., Wellman, N. A., et al (1995) Effects of tobacco smoking, schizotypy and number of pre-exposures on latent inhibition in healthy subjects. Personality and Individual Differences, 19, 893-902.
2. Andreasen, N. C. (1987) The Comprehensive Assessment of Symptoms and History (CASH). Iowa City. IA: University of Iowa.
3. Baruch, I., Hemsley, D. R. & Gray, J. A. (1988) Differential performance of acute and chronic schizophrenics on a latent inhibition task. Journal of Nervous and Mental Disease, 176, 598-606.
4. Bazire, S. (1995) Psychotropic Drug Directory. Lundbeck Publication.
5. Bleuler, E. (1913) Dementia praecox or the group of schizophrenias. Translated into English in The Clinical Routes of the Schizophrenia Concept (eds J. Cutting & M. Shephard). Cambridge: Cambridge University Press.
6. Claridge, G. S. & Broks, P. (1985) Schizotypy and hemisphere function. I: Theoretical considerations and measurement of schizotypy. Personality and Individual Differences, 5, 633-648.
7. Claridge, G. (ed.) (1997) Schizotypy: Implications for Illness and Health. Oxford: Oxford University Press.
8. Collett, D. (1994) Modelling Survival Data in Medical Research. London: Chapman & Hall.
9. Cox, D. R. & Oakes, D. (1984) Analysis of Survival Data. London: Chapman & Hall.
10. Dunn, L. A., Atwater, G. & Kilts, C. D. (1993) Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioural model of clinical drug action. Psychopharmacology, 112, 315-323.
11. Eysenck, H. J. & Eysenck, S. B. G. (1975) Manual of the Eysenck Personality Questionnaire. London: Hodder & Stoughton.
12. Frith, C. D. (1992) The Cognitive Neuropsychology of Schizophrenia. Hove: Lawrence Erlbaum.
13. Ginton, A., Urca, G. & Lubow, R. E. (1975) The effects of preexposure to an unattended stimulus on subsequent learning: latent inhibition in adults. Bulletin of the Psychonomic Society, 5, 5-8.
14. Gray, J. A., Feldon, J., Rawlins, J. N. P., et al (1991) The neuropsychology of schizophrenia. Behaviour and Brain Sciences, 14, 1-84.
15. Gray, N. S., Hemsley, D. R. & Gray, J. A. (1992a) Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurology, Psychiatry and Brain Research, 1, 83-89.
16. _, Pickering, A. D., Hemsley, D. R., et al (1992b) Abolition of latent inhibition by a single 5 mg dose of D-amphetamine in man. Psychopharmacology, 107, 425-430.
17. _, Pilowsky, L. S., Gray, J. A., et al (1995) Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophrenia Research, 17, 95-107.
18. Guterman, Y., Josiassen, R. C., Bashore, T. E., et al (1996) Latent inhibition effects reflected in event-related brain potentials in healthy controls and schizophrenics. Schizophrenia Research, 20, 315-326.
19. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. American Journal of Psychiatry, 153, 948-950.
20. Liddle, P. F. (1987) The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. British Journal of Psychiatry, 151, 145-151.
21. Lubow, R. E. (1989) Latent Inhibition and Conditioned Attention Theory. Cambridge: Cambridge University Press.
22. _, Weiner, I., Schlossberg, A., et al (1987) Latent inhibition and schizophrenia. Bulletin of the Psychonomic Society, 25, 464-467.
23. _ & Gewirtz, J. C. (1995) Latent inhibition in humans: data, theory and implications for schizophrenia. Psychological Bulletin, 117, 87-103.
24. Lukoff, D., Neuchterlein, K. H. & Ventura, J. (1986) Manual for Expanded Brief Psychiatric Rating Scale (BPRS). Schizophrenia Bulletin, 12, 594-601.
25. Norusis, N. (1993) Advanced Statistics. Chicago, IL: SPSS Inc.
26. Swerdlow, N. R., Braff, D. L., Hartston, H., et al (1996) Latent inhibition in schizophrenia. Schizophrenia Research, 20, 91-103.
27. Weiner, I., Israeli-Telerant, A. & Feldon, J. (1987) Latent inhibition is not affected by acute or chronic administration of 6 mg/kg dl-amphetamine. Psychopharmacology, 91, 345-351.
28. Williams, J. H., Wellman, N. A., Geaney, D. P., et al (1996) Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomised controlled trial of the effects of haloperidol on latent inhibition in healthy people. Biological Psychiatry, 40, 1135-1143.
29. _, _, _, et al (1997) Enhancement of latent inhibition by 1.0 mg intravenous haloperidol in two visual tasks: a randomised controlled trial in healthy people. Psychopharmacology, 133, 262-268.
30. Wolkin, A., Brodie, J. D., Barouche, F., et al (1989) Dopamine receptor occupancy and plasma haloperidol levels. Archives of General Psychiatry, 46, 482-483.
31. World Health Organization (1992) The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: WHO.
32. Yee, B. K., Feldon, J. & Rawlins, J. N. P. (1995) Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region but this lesion effect can be prevented by systemic haloperidol treatment. Behavioral Neuroscience, 109, 227-240.